| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Outlook Therapeutics, Inc. (OTLK) has 10 insiders with recent SEC Form 4 filings, including 14 buys and 5 sells. OTLK is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 3.46M | $5.46M | +24.03M | |
| CEO | 800.0K | $1.26M | - | |
| Dir | 423.7K | $669.4K | +400.0K | |
| Dir | 286.7K | $453.0K | - | |
| Dir | 117.3K | $185.3K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 10, 2019 | Hilzinger Kurt J | Director | Buy | 8,845 | $0.71 | $6,275.26 | +4.5% | |
| Jan 8, 2019 | Hilzinger Kurt J | Director | Buy | 17,781 | $0.62 | $11,082.03 | +7.1% | |
| Jan 3, 2019 | Hilzinger Kurt J | Director | Buy | 17,189 | $0.59 | $10,141.51 | +8.3% | |
| Dec 28, 2018 | Hilzinger Kurt J | Director | Buy | 18,354 | $0.53 | $9,651.06 | +13.1% | |
| Dec 24, 2018 | Hilzinger Kurt J | Director | Buy | 4,713 | $0.65 | $3,074.58 | +6.0% | |
| Dec 21, 2018 | Thurman Randy H | Director | Buy | 15,000 | $0.68 | $10,251.00 | New | |
| Sep 18, 2018 | Kenyon Lawrence A | CEO, Pres, CFO, Treas &Secy | Sell | 10,100 | $0.87 | $8,807.20 | -15.0% | |
| Jun 25, 2018 | Bahrt Kenneth | Chief Medical Officer | Sell | 7,700 | $0.85 | $6,507.27 | -14.0% | |
| Jan 4, 2018 | Mohan Pankaj | President &CEO | Sell | 114,677 | $1.17 | $134,067.48 | -0.8% | |
| Dec 22, 2017 | Yamashita Elizabeth A. | VP, Regulatory Affairs | Sell | 16,170 | $1.13 | $18,272.10 | -20.0% |